Filtered By:
Condition: Hypertension
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 587 results found since Jan 2013.
Ginsenoside Rg1 ameliorates hypoxia-induced pulmonary arterial hypertension by inhibiting endothelial-to-mesenchymal transition and inflammation by regulating CCN1
Biomed Pharmacother. 2023 May 20;164:114920. doi: 10.1016/j.biopha.2023.114920. Online ahead of print.ABSTRACTPulmonary arterial hypertension (PAH) is a chronic obstructive disease characterized by vascular remodeling. Studies have confirmed that ginsenoside Rg1 can improve pulmonary hypertension to a certain extent, but the potential mechanism by which it improves hypoxia-induced PAH remains unclear. The aim of this study was to investigate the therapeutic effect of ginsenoside Rg1 on hypoxia-induced PAH. The results showed that hypoxia promoted inflammation, EndMT, and vascular remodeling, which were accompanied by decre...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - May 22, 2023 Category: Drugs & Pharmacology Authors: Bai-Lin Tang Yu Liu Jing-Liang Zhang Mei-Li Lu Hong-Xin Wang Source Type: research
MicroRNA-31 regulates TNF- α and IL-17A co-induced-endothelial cell apoptosis by repressing E2F6
In conclusion, TNF-α and IL-17A generated in the aortic vascular tissue and serum from Ang II-induced hypertensive mice could trigger VECs apoptosis by the miR-31/E2F6 axis. To sum up, our study suggests that the key factor between cytokine co-stimulation effect and VEC apoptosis was miR-31/E2F6 axis, which was mainly regulated by NF-қB signaling pathway. This gives us a new sight to treat hypertension-associated VR.PMID:37178508 | DOI:10.1016/j.bbrc.2023.05.012
Source: Cell Research - May 13, 2023 Category: Cytology Authors: Zilong Fang Xinran Tong Guangzheng Shi Wendong Chen Qun Li Source Type: research
< em > SOX17 < /em > Enhancer Variants Disrupt Transcription Factor Binding And Enhancer Inactivity Drives Pulmonary Hypertension
CONCLUSIONS: Common PAH risk variants upstream of the SOX17 promoter reduce endothelial SOX17 expression, at least in part, through differential binding of HOXA5 and ROR-α. Reduced SOX17 expression results in disturbed hPAEC function and PAH. Existing drug compounds can reverse the disturbed SOX17 pulmonary endothelial transcriptomic signature.PMID:37066790 | DOI:10.1161/CIRCULATIONAHA.122.061940
Source: Circulation - April 17, 2023 Category: Cardiology Authors: Rachel Walters Eleni Vasilaki Jurjan Aman Chien-Nien Chen Yukyee Wu Olin D Liang Ali Ashek Olivier Dubois Lin Zhao Farah Sabrin In ês Cebola Jorge Ferrer Nicholas W Morrell James R Klinger Martin R Wilkins Lan Zhao Christopher J Rhodes Source Type: research
Inhibition of poly (ADP-ribose) Polymerase-1 (PARP-1) improves endothelial function in pulmonary hypertension
Pulm Pharmacol Ther. 2023 Feb 24:102200. doi: 10.1016/j.pupt.2023.102200. Online ahead of print.ABSTRACTEndothelial dysfunction is critical in the pulmonary vasculature during pulmonary hypertension (PH). Moreover, in PH, increased inflammation and oxidative/nitrosative stress cause DNA damage, activating poly (ADP-ribose) polymerase-1 (PARP-1). Meloche et al. (2014) and our previous research have shown that inhibiting PARP-1 is protective in PH and associated RV hypertrophy. However, the role of PARP-1 in pulmonary arterial endothelial dysfunction has not been explored completely. Therefore, the current study aims to inve...
Source: Cell Research - February 26, 2023 Category: Cytology Authors: Mohammad Shafiq Zahid Rasool Lone Adam Olaitan Abdulkareem Gurpreet Kaur Sai Navya Himalaya Singh Kumaravelu Jagavelu Kashif Hanif Source Type: research
Astragaloside IV improves pulmonary arterial hypertension by increasing the expression of CCN1 and activating the ERK1/2 pathway
In conclusion, AS-IV improves PAH by increasing the expression of CCN1 and activating the ERK1/2 signalling pathway. The results of our study provide a theoretical basis for additional study on the protective effect of AS-IV against PAH.PMID:36762748 | DOI:10.1111/jcmm.17681
Source: Molecular Medicine - February 10, 2023 Category: Molecular Biology Authors: Yu Liu Bai-Lin Tang Mei-Li Lu Hong-Xin Wang Source Type: research
Can siRNA Improve Compliance in Patients With Hypertension? Can siRNA Improve Compliance in Patients With Hypertension?
Patients achieve a reduction in systolic blood pressure of>15 mm Hg for as long as 8 weeks after administration of a single dose of zilebesiran.Medscape Medical News
Source: Medscape Cardiology Headlines - January 13, 2023 Category: Cardiology Tags: Cardiology News Source Type: news
Petits ARN interf érents : applications potentielles pour les néphrologues Small interfering RNA: potential applications for nephrologists
Nephrol Ther. 2022 Dec;18(6S1):6S1-6S6. doi: 10.1016/S1769-7255(22)00646-0.ABSTRACTSmall interfering RNA (siRNAs) are double-stranded RNAs of around 20 base pairs in length that trigger RNAi machinery, which promotes degradation of a target mRNA avoiding protein translation. SiRNAs are liver-targeted, using tris N-acetylgalactosamine (GalNAc) as the targeting ligand. This discovery received the Nobel Prize for medicine and physiology in 2006 and lead to substantial therapeutic advances. Application field and development of these siRNA has been very fast. Indeed, patisiran has been released in 2018 for hereditary transthyre...
Source: Nephrologie and Therapeutique - December 30, 2022 Category: Urology & Nephrology Authors: Sandrine Lemoine Marie Courbebaisse Source Type: research
